Scientific American custom media and Immunomic Therapeutics, Inc. wrote this article titled, “After the Gold Rush.”

Immuno-oncology (IO) has seen a flood of advancements, investment deals and partnerships, but the climate is changing. How might IO 2.0 drive companies to operate and partner differently?

Click here to read:  https://www.scientificamerican.com/custom-media/after-the-gold-rush/